211 421

Cited 0 times in

Cited 9 times in

Achievement of LDL-C targets defined by ESC/EAS (2011) guidelines in risk-stratified Korean patients with dyslipidemia receiving lipid-modifying treatments

Authors
 Yang, Ye Seul  ;  Lee, Seo Young  ;  Kim, Jung-Sun  ;  Choi, Kyung Mook  ;  Lee, Kang Wook  ;  Lee, Sang-Chol  ;  Cho, Jung Rae  ;  Oh, Seung-Jin  ;  Kim, Ji-Hyun  ;  Choi, Sung Hee 
Citation
 Endocrinology and Metabolism(대한내분비학회지), Vol.35(2) : 367-376, 2020-06 
Journal Title
Endocrinology and Metabolism(대한내분비학회지)
ISSN
 2093-596X 
Issue Date
2020-06
Keywords
Cholesterol ; Dyslipidemias ; Hydroxymethylglutaryl-CoA reductase inhibitors ; Korea ; LDL ; Practice guideline ; Risk assessment
Abstract
Background: This study assessed the proportion of risk-stratified Korean patients with dyslipidemia achieving their low-density lipoprotein cholesterol (LDL-C) targets as defined by the European Society of Cardiology/European Atherosclerosis Society (ESC/ EAS) (2011) guidelines while receiving lipid-modifying treatments (LMTs). Methods: In this multicenter, cross-sectional, observational study, we evaluated data from Korean patients aged ≥19 years who were receiving LMTs for ≥3 months and had an LDL-C value within the previous 12 months on the same LMT. Data were collected for demographics, cardiovascular (CV) risk factors, medical history, and healthcare consumption. Patients were risk-stratified according to the ESC Systematic COronary Risk Evaluation (SCORE) chart and LDL-C target achievement rate was assessed. Results: Guideline-based risk-stratification of the 1,034 patients showed the majority (72.2%) to be in the very high-risk category. Investigators' assessment of risk was underestimated in 71.6% compared to ESC/EAS guidelines. Overall LDL-C target achievement rate was 44.3%; target achievement was the highest (66.0%) in moderate-risk patients and the lowest (39.0%) in very high-risk patients. Overall 97.1% patients were receiving statin therapy, mostly as a single-agent (89.2%). High-intensity statins and the highest permissible dose of high-intensity statins had been prescribed to only 9.1% and 7.3% patients in the very high-risk group, respectively. Physician satisfaction with patients' LDL-C levels was the primary reason for non-intensification of statin therapy. Conclusion: Achievement of target LDL-C level is suboptimal in Korean patients with dyslipidemia, especially in those at very high-risk of CV events. Current practices in LMTs need to be improved based on precise CV risk evaluation posed by dyslipidemia. © 2020 Korean Endocrine Society
DOI
10.3803/EnM.2020.35.2.367
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Jung Sun(김중선) ORCID logo https://orcid.org/0000-0003-2263-3274
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/184894
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links